On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – iCAD, Inc. (NASDAQ: ICAD) Utilizes Proprietary Algorithm and Artificial Intelligence with PowerLook Tomo Detection

Company: iCAD, Inc. (ICAD)
Category: Stock Spotlights

iCAD (NASDAQ: ICAD) provides advanced image analysis, workflow solutions and radiation therapy for the early detection and treatment of cancer. Breast cancer is the most common cancer in women, regardless of race or ethnicity. According to the American Cancer Society, 292,130 women were diagnosed with breast cancer in the U.S. in 2015 alone. In an effort to help shrink fatal outcomes of these statistics, iCAD recently launched PowerLook Tomo Detection, which is designed to make reading digital breast tomosynthesis scans (an advanced type of mammogram that can offer better cancer detection, fewer call backs and greater peace of mind) less time consuming for radiologists to read. The solution operates on an algorithm that employs artificial intelligence and deep learning, and can detect suspicious patterns that may indicate cancer. PowerLook Tomo Detection is commercially available in Europe and pending FDA-approval in the United States.

To learn more visit www.icadmed.com or www.xoftinc.com

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.networknewswire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217